Fate Therapeutics Inc $FATE

What the company doesAI summary of filing

Fate Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf cellular immunotherapies using its proprietary induced pluripotent stem cell (iPSC) platform. The company engineers iPSCs to create clonal master cell lines that can be mass-produced into uniform T-cell and natural killer (NK) cell therapies incorporating multiple synthetic controls of cell function. The company is advancing a pipeline of iPSC-derived CAR T-cell and CAR NK cell candidates for autoimmune diseases and solid tumors, with FT819 currently in Phase 1 clinical trials for systemic lupus erythematosus and FT825 in Phase 1 for solid tumors. Fate is pre-revenue and funds operations through research and development fees from its collaboration with Ono Pharmaceutical and grant funding. [10-K 2026-02-26]

Segments: FT819 (CAR T-cell, autoimmune diseases), FT825 (CAR T-cell, solid tumors), FT836 (CAR T-cell, solid tumors), FT522 (CAR NK cell, autoimmune diseases and B-cell lymphoma)